RxDoctor Payments Data

Margaret Foss, APRN

Nurse Practitioner · Westwood, KSNPI 1114481199

Payments from drug & device makers

$1,472in general payments, 2019–2025

Across 16 payments — averaging $91.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$422
  • Janssen Scientific Affairs, LLC$340
  • Pfizer$150
  • Sanofi$123
  • E.r. Squibb & Sons, L.L.C.$114
  • GSK$103
  • plus $220 from 4 others
$15,792in research payments, 2019–2025

Across 7 payments — averaging $2255.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$16K

What the payments were for

  • Consulting fees$49033%
  • Food & beverage$56038%
  • Education$42229%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,472 in reported general payments places this provider in the 80th percentile of 1,326 nurse practitioner providers in Kansas.

See all nurse practitioner providers in Kansas

Medicare billing

Part B allowed, 2024
$31,155
Medicare patients
237
Services billed
519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide59$1,049,156
PomalystPomalidomide23$485,622
Lenalidomide25$382,257
EliquisApixaban27$23,669
XareltoRivaroxaban32$22,262
Acyclovir85$1,908
Hydrocortisone11$916
Morphine Sulfate ErMorphine Sulfate24$912
Oxycodone Hcl43$645
Duloxetine Hcl18$385
Gabapentin42$349
Potassium Chloride16$322
Dexamethasone29$320
Pantoprazole Sodium14$233
Levothyroxine Sodium11$151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$114$485,62223 claims
PfizerEliquis$150$23,66927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,326 nurse practitioner providers in Kansas.

Other nurse practitioner in Westwood

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →